Colorectal Cancer Clinical Trial
Official title:
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Only an estimated 50 million US adults aged 50-75 are up-to-date on colorectal cancer (CRC)
screening according to guidelines set by the federal government. CRC is 90% curable with
timely detection and appropriate treatment of precancerous polyps; increased screening could
reduce incidence by up to 50%. Groups least likely to undergo screening, those with minimal
education, low income, low access to health care, recent immigrants or Hispanics, are the
same people who frequently receive care at Federally Qualified Healthcare Center's (FQHCs).
The use of fecal occult blood tests (FOBT) and fecal immunochemical tests (FIT) is
exceedingly low in FQHCs (7-9% of patients in the past year) and far below national averages
and target rates. Our results will provide valuable information on how to use electronic
health record (EHR) resources to optimize guideline-based screening in FQHC clinics whose
patient populations have disproportionately low CRC screening rates.
This project, in conjunction with the research team, will use an advisory panel to direct the
research activities. The advisory panel will be made up of clinicians, leaders, researchers,
and patients. The panel and team will guide the development of materials, the outreach to
patients, and the research protocol to best reach FQHC patients who are due for colorectal
cancer screening.
This project will be conducted in two phases, Phase I is conducting a pilot at two FQHC's,
and Phase II is rolling out the intervention to between 20-30 clinics.
Phase I (Pilot Aims)
- Aim 1 Conduct preliminary analyses of EHR data at two pilot clinics.
- Aim 2: Use codes and methods developed in Aim 1 to test the feasibility, reach,
effectiveness, and cost of an EHR-based CRC screening intervention using a subset of 100
patients at each of two pilot clinics. We will use codes defined in Aim 1 to create a
Solutions-based, Epic-integrated system to track CRC screening, mail FIT kits, and track
patient test results and receipt of follow-up care. The system will be pilot-tested in
two clinics.
- Aim 3: Use results from the pilot intervention to prepare for a large-scale,
cluster-randomized pragmatic trial across 18 OCHIN clinics (see Phase II).
Transition from Phase I to Phase II
-Changes to our original proposal include going from a three arm to a two-arm pragmatic
cluster trial with revised evaluation and power calculation and refinements to the
intervention components for both usual care (now described as enhanced usual care) and the
intervention (now described as enhanced auto).
Phase II (Full trial Aims)
- Primary Aim 1. Assess the effectiveness of a large-scale, two-arm CRC screening program
among diverse CLINIC patients, and assess difference in CRC screening outcomes (overall
and by age, sex, insurance status, Hispanic ethnicity/race). The intervention will
consist of an automated data-driven, EHR-linked program for mailing FIT kits (with
linguistically appropriate pictographic instructions and return postage) to patients due
for CRC screening.
- Primary Aim 2. Assess the costs and long-term cost-effectiveness of the automated
program.
We have also included two secondary aims:
- Secondary Aim 1. Assess adoption, implementation, reach and potential maintenance and
spread of the program, using a mixed-method rapid assessment process, field notes, and
other ethnographic data.
- Secondary Aim 2. Adapt and pilot-test the adaptation of STOP CRC in an alternate EHR
platform, Allscripts, and develop an implementation guide to assist sites in adopting
the program.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |